ESCRS Homepage

September 2003
IN THIS ISSUE

New device creates alcohol-free epithelial flaps to improve healing and reduce haze


New IOL fixes suture-free in capsule-less eyes

Researchers race to produce bionic vision

Implantable telescope shows promise in AMD

New IOL Tackles Anterior-Capsule-Related Complications

Prospective study shows water jet phaco as effective as ultrasound for majority of cataracts

Laser microkeratome may reduce flap complications and improve visual outcome

Customised wavefront-guided ablation: exciting technology but beware the hype

Multifocal ablation results promising in presbyopia

In line phaco-filter aims to improve safety

Studies link genes to age-related cataract

Human genome project yielding clues to the aetiology of many ophthalmic disorders

New IOL 'adjusts' postoperatively to target refraction

Cold phaco heats up as new era dawns

Hartmann-Shack aberrometer finds new application in evaluation of nuclear cataract

Refractive surgery can improve quality of life - survey

Large retrospective study supports early intervention in paediatric cataracts

Study tracks blade influence on flap thickness

Study shows multifocal IOL implantation provides good binocular vision

Study revives hyperopic LASIK centration debate

Phakic IOL better than LASIK for high myopia

Getting to grips with ocular herpes

New rounded IOL edge design reduces glare

25-gauge vitrectomy needle speeds surgery

Indications for botulinum toxin treatment continue to expand

Experts debate value of customised ablation

FEATURES
From The Editor
Reflections on Refractive Surgery
Prime Site
Bio-ophthalmology
Eye On Travel
Collectors Eye
Regulatory Matters


Indications for botulinum toxin treatment continue to expand

Stefanie Petrou-Binder MD in Nürnberg

BOTULINUM toxin A is an effective treatment option for spastic entropion, according to a study presented at the XVI Annual Meeting of German Surgeons (DOC).
Daniela Claessens MD injected botulinum toxin (Dysport, Ipsen/Botox, Allergan) in ten eyes of ten patients with spastic entropion of the lower lid to achieve eversion of the lower lid. Entropion surgery in these patients was either contraindicated or the patients did not consent to the operation. Patients' diagnoses ranged from spastic entropion in eight patients, to one case of ocular pemphigoid, and one case of trachoma.

In the three to ten days following the procedure, Dr. Claessens reported that nine of the study patients with successfully everted lower lids were symptom free. In one patient, she administered another 20 IU two weeks later following the development of trichiasis. She further noted that one patient developed a small haematoma and four of the patients experienced viral-like symptoms. The paralysis induced by botulinum toxin A lasted for three to six months.

To prepare the injection solution, Dr. Claessens took 2.5 ml of sterile sodium chloride and 500 IU of botulinum toxin and injected them into the injection bottle, which produced a clear solution of 20 IU per 0.1 ml. After disinfecting the skin, she allowed a period of five minutes to elapse to avoid any denaturisation of the protein components of the botulinum toxin by the alcohol.

Using a 20-gauge needle, Dr. Claessens injected a total of 60 IU of botulinum toxin A at two different sites in the orbicular muscle of the lateral lower lid in all ten patients. She was able to monitor the dosage during the administration by implementing a 1.0 ml syringe with a 0.01 ml scale.
She applied a simple ice pack to control pain immediately following the injection and to counteract the diffusion of the toxin through vasoconstriction. She then observed the patients for one hour following the procedure to rule out the possibility of an allergic reaction to the drug. She carefully monitored her patients for two weeks.

Dr. Claessens explained that the contraindications for this procedure included disturbances of the motor endplate, hypersensitivity to one of the components of the drug, simultaneous treatment with aminoglycoside antibiotics, marked chronic respiratory complaints, deglutition complaints, disturbances in coagulation, infection at injection site, and pregnancy or nursing.
The possible reversible general side effects included haematoma, temporary exaggerated muscle weakness at injection site, and the involvement of other muscles through diffusion.

More specifically to the toxin itself, she noted that ectropion and double vision could occur if the injection is given too far medially, through diffusion to the inferior oblique muscle. These potential side effects are reversible.
She stressed that the therapeutic employment of botulinum toxin outside of the established indications requires a detailed discussion and informed consent of the patient.

In a related presentation, Peter Roggenkaemper MD reviewed the manifold uses of botulinum toxin that range from the clinical to the purely cosmetic.
"Aside from spastic entropion, other indications for botulinum injection include the treatment of wrinkles (Crow's feet, glabellar wrinkles), to attain protective ptosis in poorly healing corneal ulcers, for stopping hypersecretion of the lacrimal glands, and for treatment of blepharo- and hemifacial spasms," he said.
He reported that he had seen excellent results in alleviating lid spasms in series of more than 2400 cases of blepharospasm, which had effectively blinded many of his patients due to the severity of the spasm. The effects of the treatments usually lasted three to four months, with considerable variation in the effective dosage and duration of action among patients.

He commented that patients could be treated over the long term with little or no diminution of the effects. He cited examples of patients who had been injected up to ninety times over a period of many years.
He explained that although the inhibition of the neurotransmitter acetylcholine by botulinum is irreversible, new receptors begin to sprout within the neuromuscular junction after a few weeks, which allow the muscle to resume its function.

According to Dr Roggenkaemper, the worst complication involved with Botox treatment is ptosis, which can be avoided by injecting at a small distance from the levator muscle. Should this complication occur, however, it will persist for several months until the action of the toxin is overcome by new acetylcholine receptors.
In the 5%-10% of blepharospasm cases for which botulinum injection is ineffective, Dr Roggenkaemper performs suspension surgery, which is well tolerated by patients, he added.


Daniela Claessens MD
Fax: + 49 221 407 200
Peter Roggenkaemper MD
University Eye Clinic, Bonn, Germany
proggenk@uni-bonn.de

Top